Mirati Therapeutics, Inc. ("Mirati") (NASDAQ: MRTX) today presented data that demonstrated preliminary evidence of clinical activity from its investigational targeted tyrosine kinase inhibitor candidate, MGCD265, as part of the developmental therapeutics category at the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting being held in Chicago from May 29-June 2, 2015. The Company also provided updates on its other targeted tyrosine kinase inhibitor, MGCD516, and spectrum-selective HDAC inhibitor, mocetinostat. Both MGCD516 and mocetinostat were presented as clinical trials in progress at the conference.
"New cancer therapies specifically targeting genetic drivers in selected patients may represent a significant advance compared to traditional chemotherapy," said Christian Kollmannsberger, M.D., British Columbia Cancer Agency, Vancouver Cancer Centre. "MGCD265 is a receptor tyrosine kinase inhibitor that selectively targets tumors in patients with MET or Axl gene alterations. In an ongoing single agent expansion study of MGCD265 in non-small cell lung cancer patients with these alterations, we have seen significant tumor regression in three patients as well as improvement in clinical symptoms such as pain and shortness of breath. Data from this study indicate that MGCD265 can fully inhibit MET and Axl, is well tolerated and should be studied further to define the benefit to patients with lung cancer."
"Data from the Phase 1/1b expansion study presented today clearly demonstrate the anti-tumor activity of MGCD265 and support our hypothesis that targeting MET driver alterations is a clinically valid approach. MGCD265 is the first MET inhibitor targeting MET mutations, MET gene amplification and Axl rearrangements. Collectively, these driver alterations comprise up to 8% of patients with non-small cell lung cancer," said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. "We are very encouraged by the initial results from this study. The first three non-small cell lung cancer patients with MET exon 14 deletion mutations or MET gene amplification showed clear tumor regression as early as the first assessment and the trial continues to enroll additional patients. Treatment was well tolerated in dose escalation and dose expansion cohorts and PK/PD data demonstrated robust inhibition. These data increase our confidence in the program and we expect to initiate a single arm registration-enabling study in NSCLC by the end of the year."
MGCD265 Phase 1/1b Study, Expansion Cohort:
MGCD265 is an inhibitor of the MET and Axl receptor tyrosine kinase pathways which, when mutated, are drivers of tumor growth. Preclinical data have shown that MGCD265 can potently inhibit tumor cell growth in vitro. Tumor xenograft data demonstrated that tumors with MET exon 14 deletion mutations or MET gene amplification treated with MGCD265 resulted in complete tumor regression, and were predictive of clinical data observed in the ongoing MGCD265 expansion study. This open label, single agent study is designed to evaluate the safety, tolerability, pharmacokinetics/pharmacodynamics (PK/PD) and clinical activity of twice-daily (BID) MGCD265 in patients who have failed at least one prior therapy.
This multinational study began enrollment at the end of December 2014 and continues to enroll NSCLC patients with MET or Axl genetic alterations.
Evidence of clinical activity
Patients receive 1050 mg of MGCD265 BID for 21-day cycles and are assessed for response after every second treatment cycle. At the time of this initial analysis, the first three NSCLC patients with MET gene alterations showed a clinical benefit, including clear tumor regression and improvement in clinical symptoms such as pain and shortness of breath. Currently, these patients do not meet strict criteria for RECIST responses. Patient details are noted below. (The MGCD265 Phase 1/1b study poster presented at ASCO contains additional information, including patient scans noted below, and can be found on the Company's website at www.mirati.com.)
- 76-year old male: Adenocarcinoma of the lung with a MET exon 14 deletion mutation. The patient enrolled in the study with lung metastases, retroperitoneal and retrocrural lymph nodes and pleural effusion. The patient had undergone platinum-based chemotherapy followed by PD-L1 inhibitor therapy with the best response to each therapy being progressive disease. The first scan after treatment with MGCD265 demonstrated cavitation of the lung/retroperitoneal mass with resolution of pain and cough. The patient continues on the study and is currently in Cycle 5.
- 70-year old female: History of refractory metastatic adenocarcinoma of the lung with a MET exon 14 deletion mutation. The patient enrolled in the study with extensive liver metastases, right pulmonary lesion and had undergone neoadjuvant chemoradiation, radical pneumonectomy for T3N1 disease, received chemoradiation for pleural and bone metastases, Stereotactic Body Radiation Therapy (SBRT) for pulmonary metastatis, and resection of recurrence in the colon. The first scan after treatment with MGCD265 showed extensive tumor necrosis and regression. The patient continues on the study and is currently in Cycle 6.
- 51-year old female: Adenocarcinoma of the lung with MET amplification. The patient enrolled in the study with extensive lung disease, bone and brain metastases. The patient had received an EGFR inhibitor, undergone chemotherapy and whole brain radiation. The first scan after treatment with MGCD265 demonstrated regression of tumors in the lung. The patient continues on the study and is currently in Cycle 3.
Safety and tolerability
In the dose escalation phase of the study, the maximum tolerated dose of MGCD265 was 1050 mg BID. This dose was shown to result in >90% inhibition of MET and Axl based on preclinical predictions and biomarkers sMET and sAxl. The dose limiting toxicities were grade 3 fatigue in one patient and grade 3 diarrhea in one patient. In the dose escalation cohort, MGCD265 was well tolerated at the 1050 mg BID dose and diarrhea in subsequent patients is managed with standard doses of the anti-diarrhea agent loperamide.
The Company expects to initiate a single arm Phase 2 registration-enabling study in NSCLC by the end of the year.
"While the initial focus of the single agent MGCD265 program is on non-small cell lung cancer, MET is a critical driver in other solid tumors. As approximately five percent of gastric cancer patients have MET gene amplification, gastric cancer represents a significant area for expanded development and, we believe, that MGCD265 could result in clinically meaningful responses in this underserved patient population," said Charles M. Baum, M.D., Ph.D., president and CEO, Mirati. "In addition to the single agent opportunity in NSCLC, there is a strong scientific rationale for the combination of MGCD265 with a third-generation EGFR inhibitor. Recent data have reinforced the hypothesis that MET and Axl may play an important role in resistance to EGFR inhibition. We are exploring our options and plan to start a combination study in patients who are becoming resistant to EGFR inhibition."
The MGCD265 Phase 1/1b study poster presented at ASCO can be found on the Company's website at www.mirati.com. Additional information about this clinical trial of MGCD265 is available at www.clinicaltrials.gov using identifier: NCT00697632.
Mocetinostat Phase 2 Study in Urothelial Bladder Cancer (UC):
Mocetinostat is a spectrum-selective histone deacetylase (HDAC) inhibitor. This single arm, single agent Phase 2 clinical trial is designed to evaluate the efficacy, safety, tolerability and PK of mocetinostat as a treatment for a select group of patients with advanced urothelial carcinoma of the bladder.
The primary objective of the study is to determine the clinical activity of mocetinostat in patients with previously treated, locally advanced, unresectable or metastatic urothelial carcinoma of the bladder harboring inactivating mutations or deletions of the histone acetyltransferase genes CREBBP and/or EP300 (estimated to occur in approximately 20% of bladder cancer patients). Secondary objectives include evaluation of safety, secondary efficacy endpoints and PK. Mocetinostat is administered orally three times per week on a 28-day cycle.
The mocetinostat Phase 2 study poster presented at ASCO can be found on the Company's website at www.mirati.com. Additional information about this clinical trial of mocetinostat is available at www.clinicaltrials.gov using identifier: NCT02236195.
MGCD516 Phase 1 Study in NSCLC:
MGCD516 is a receptor tyrosine kinase (RTK) inhibitor targeting the RET, DDR and Trk tyrosine kinase signaling pathways, which are reported to be oncogenic drivers. This Phase 1, open label, single agent study is designed to evaluate the safety, PK/PD and clinical activity of MGCD516 in patients with advanced solid tumors, with an initial focus on NSCLC.
The primary objective of the dose escalation phase of the study is to characterize the safety of MGCD516, determine a Phase 2 dose and establish the maximum tolerated dose. MGCD516 is orally administered to unselected patients with advanced solid tumors once daily (QD) on a 21-day cycle. The study is exploring escalating doses of 10 mg, 20 mg, 40 mg, 80 mg and 110 mg to date. Patients have been enrolled across all dosing cohorts and dose escalation will continue until a maximum tolerated dose is established.
The MGCD516 Phase 1 study poster presented at ASCO can be found on the Company's website at www.mirati.com. Additional information about this clinical trial of MGCD516 is available at www.clinicaltrials.gov using identifier: NCT02219711.
Mirati to Present at Jefferies 2015 Global Healthcare Conference
Mirati will also be presenting at the Jefferies 2015 Global Healthcare Conference on Wednesday, June 3 at 8:00 a.m. ET/5:00 a.m. PT in New York. Charles M. Baum, M.D., Ph.D., president and CEO of Mirati, will provide a corporate overview.
Mirati Therapeutics, Inc.